Antibodies to soluble liver antigen and alpha-enolase in patients with autoimmune hepatitis.
J Autoimmune Dis 2004; 1(1):4. – DOI: 10.1186/1740-2557-1-4
Autoimmune liver serology: Current diagnostic and clinical challenges.
World J Gastroenterol 2008 June 7; 14(21): 3374-3387 – DOI: 10.3748/wjg.14.3374
Disease-specific autoantibodies in primary biliary cirrhosis.
Clin Chim Acta 412 (7-8):502-512, 2011.
Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis.
Hepatology 45 (6):1583-1584, 2007.
Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis.
J Clin.Pathol. 59 (3):280-284, 2006.
Primary biliary cirrhosis: what do autoantibodies tell us?
World J Gastroenterol. 16 (29):3616-3629, 2010.
Autoimmune hepatitis, from mechanisms to therapy.
Hepatology 2006; 43(2 Suppl 1):S132-S144. – DOI 10.1002/hep.21059
The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.
Gut 1998;42:599–602
The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome
Am J Gastroenterol. 104 (6):1420-1425, 2009.
Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus- associated chronic liver diseases
Clin Exp Immunol. 1995 April; 100(1): 67–74.
Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis.
J Autoimmune.Dis 4:2, 2007.
Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis
Group J Hepatol. 41 (4):677-683, 2004.
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.
Lancet 2000; 355(9214):1510-5. – DOI:10.1016/S0140-6736(00)02166-8
Antinuclear antibodies specific for primary biliary cirrhosis.
Autoimmun.Rev 2 (4):211-217, 2003.
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.
Journal of Autoimmune Diseases 2004, 1:2 – DOI:10.1186/1740- 2557-1-2
Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA.
J Clin Lab Anal 2002; 16(4):194-201.